|Day Low/High||10.48 / 10.68|
|52 Wk Low/High||6.25 / 13.76|
There continues to be a lot of interest in Teva Pharmaceutical Industries . Over the last few days I have received a number of inquiries via email. Here was my most recent analysis of about two weeks ago. I still would not bottom fish in the ...
Treasury secretary says it's baked into the market, but is anyone really counting on it?
"Drug companies are getting away with murder." - PresidentTrump And these words, corralling fears of drug price controls, are taking down Allergan , Teva (which I would sell), big pharma shares and other drug company share prices now. My sole in...
Eagle Pharmaceuticals, Aratana Therapeutics and Progenics Pharmaceuticals show promise.
Eagle Pharmaceuticals, Aratana Therapeutics and Progenics Pharmaceuticals show promise ahead.
On Wednesday I explained why I would avoid Teva Pharmaceutical Industries : I know by the Comments Section that there has been a lot of bottom fishing in Teva (TEVA) . I had done a few hours of research on the company over the last months and passed...
The three major indexes closed at record highs, the Dow for its third day in a row, the Nasdaq its fourth, and the S&P 500 its fifth.
I know by the Comments Section that there has been alot of bottom fishing in Teva . I had done a few hours of research on the company over the last months and passed on the name. I would continue to avoid the shares based, in part, on the follow...
Mylan scored FDA approval for a generic version of Teva Pharmaceuticals' multiple sclerosis drug, Copaxone.
The Israeli pharma company Teva has established a rich history since its founding in 1901. Can it continue to survive as it faces one challenge after another?
The pharmaceutical company on Oct. 3 said the FDA has approved its generic version of Teva's multiple sclerosis drug Copaxone.
Mylan's drug approval announced this morning is a big negative for Teva Pharmaceutical Industries and likely will result in a $3 to $5 drop in Allergan's shares in the early going.
Allergan is about $5 higher on strength in Teva Pharmaceutical . This is about the price at which I reduced late last week to bring the position from large to medium in size.
Stocks aim for new records with markets in a generally upbeat mood ahead of a decision on interest rates from the Federal Reserve this week.
In August 2016, Teva completed its purchase of Allergan's generic drug business for $33.4 billion in cash and $5.4 billion in stock
There are two separate and positive developments at Allergan over the last three days that should continue to buoy its shares, which were up $6 on Friday. First, as I posted over the weekend: Allergan and the Tribe Have Spoken Sep 9, 2017 ' 9:29 AM...
Teva could be on the verge of a surge similar to what 3 other companies have seen since 2008-09.
I am working incrementally into some small stocks with great long-term value.
Domestic politics take the spotlight yet again
The drug stock deserved to go down, but the resulting selloff is an overreaction.
If you want to reap big gains, read, understand and buy when the numbers make sense.